Skip Navigation


Cardiovascular Research Advance Access first published online on September 19, 2007
This version [Corrected Proof] published online on October 16, 2007
Cardiovascular Research, doi:10.1093/cvr/cvm018
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
77/2/353    most recent
cvm018v2
cvm018v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kohr, M. J.
Right arrow Articles by Ziolo, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kohr, M. J.
Right arrow Articles by Ziolo, M. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Targeting of phospholamban by peroxynitrite decreases ß-adrenergic stimulation in cardiomyocytes

Mark J. Kohr1, Honglan Wang1, Debra G. Wheeler1, Murugesan Velayutham2, Jay L. Zweier2 and Mark T. Ziolo1,*

1 Department of Physiology and Cell Biology, Davis Heart and Lung Research Institute, The Ohio State University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA
2 Department of Internal Medicine, Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH 43210, USA

* Corresponding author. Tel: +1 614 688 7905; fax: +1 614 688 7999. E-mail address: ziolo.1{at}osu.edu

Time for primary review: 27 days


   Abstract
Top
 Abstract
1. Introduction
 2. Methods
 3. Results
 4. Discussion
 Supplementary material
 Funding
 References
 
Aims: Peroxynitrite production increases during the pathogenesis of numerous cardiac disorders (e.g. heart failure). However, limited studies have investigated the mechanism through which peroxynitrite exerts anti-adrenergic effects. Thus, the purpose of this study is to investigate the contribution of phospholamban (PLB), a critical excitation–contraction coupling protein, to the peroxynitrite-induced dysfunction.

Methods and results: Isolated myocytes from wild-type (WT, CF-1) and PLB knockout (PLB–/–) mice were stimulated at 1 Hz, and myocyte shortening and Ca2+ transients were simultaneously recorded. PLB phosphorylation was measured via western blot. Myocytes were superfused with isoproterenol, a ß-adrenergic agonist, and SIN-1, a peroxynitrite donor. SIN-1 superfusion dramatically decreased isoproterenol-stimulated Ca2+ transients and myocyte shortening in WT myocytes. These effects were inhibited upon addition of the peroxynitrite decomposition catalyst, FeTPPS. Surprisingly, SIN-1 had no functional effect on ß-adrenergic-stimulated PLB–/– myocytes. Western blot analyses revealed that SIN-1 significantly decreased isoproterenol-stimulated PLBSer16 phosphorylation. Experiments with the protein phosphatase inhibitor, okadaic acid, alleviated the SIN-1-induced functional effects and the decrease in PLB phosphorylation.

Conclusions: The peroxynitrite donor SIN-1 decreases ß-adrenergic stimulation by reducing PLBSer16 phosphorylation via protein phosphatase activation. This peroxynitrite-induced decrease in PLB phosphorylation may be a key mechanism in the ß-adrenergic dysfunction observed in many cardiomyopathies.

KEYWORDS E-C coupling; SR Function; Calcium (cellular); Protein Phosphorylation; Protein Phosphatases

Received May 15, 2007; revised September 8, 2007; accepted September 13, 2007


   1. Introduction
Top
 Abstract
 1. Introduction
2. Methods
 3. Results
 4. Discussion
 Supplementary material
 Funding
 References
 
The process of excitation–contraction coupling is responsible for contraction in the cardiomyocyte.1 Following the cardiac action potential, L-type Ca2+ channels open to facilitate Ca2+ entry into the cell, triggering the opening of sarcoplasmic reticulum (SR) Ca2+ release channels (RyR) and the discharge of additional Ca2+ from the SR. This Ca2+ subsequently activates the myofilaments, resulting in myocyte contraction. Relaxation is primarily mediated by the SR Ca–ATPase/phospholamban (SERCA/PLB) complex, which serves to reuptake Ca2+ into the SR.

Phospholamban plays a critical role in excitation–contraction coupling by regulating SERCA uptake of Ca2+ into the SR, and is important in determining SR Ca2+ load and thus contractility.2 Under basal conditions, PLB remains in a dephosphorylated state and inhibits SERCA uptake of Ca2+. PLB inhibition of SERCA can be relieved when PLB is phosphorylated, allowing greater uptake of Ca2+ into the SR. For example, activation of the ß-adrenergic receptor signalling cascade leads to positive inotropic and lusitropic effects,3 which result mainly from the phosphorylation of PLB at its protein kinase A (PKA)-dependent serine 16 (Ser16) site.4 Additionally, PLB can also be phosphorylated at its Ca2+/calmodulin kinase II (CaMKII)-dependent threonine 17 (Thr17) site. There are several protein phosphatases that serve to dephosphorylate PLB, including protein phosphatase 1 (PP1) and protein phosphatase 2a (PP2a).5

Peroxynitrite (ONOO–) is formed upon the reaction of nitric oxide (NO) and superoxide (O2–). Studies have shown that peroxynitrite is increased in many cardiomyopathies including ischemia/reperfusion injury, sepsis, and heart failure and is detrimental to cardiac function.6–12 The negative effects of peroxynitrite have been confirmed in normal hearts during basal stimulation.13–15 Additionally, the peroxynitrite donor, SIN-1, was shown to have anti-adrenergic effects in isolated cardiomyocytes.16,17 However, studies have also demonstrated positive inotropy with peroxynitrite.18–20 This discrepancy may be due to the proposed biphasic nature of peroxynitrite, where peroxynitrite produces positive inotropic effects at low concentrations, but negative inotropic effects at high concentrations. Although the biphasic nature of peroxynitrite in the myocardium has been characterized, most studies have not investigated the mechanism(s) of peroxynitrite-induced ß-adrenergic hyporesponsiveness. Therefore, despite this role for peroxynitrite in the modulation of cardiac contractility, little is known regarding the mechanism(s) underlying the effect(s) of peroxynitrite.

Therefore, the objective of this study is to evaluate critically the role of PLB in the peroxynitrite-induced ß-adrenergic hyporesponsiveness. We hypothesize that peroxynitrite ultimately targets PLB and selectively decreases PKA-dependent Ser16 phosphorylation via activation of protein phosphatases.


   2. Methods
Top
 Abstract
 1. Introduction
 2. Methods
3. Results
 4. Discussion
 Supplementary material
 Funding
 References
 
2.1. Cardiomyocyte isolation
Ventricular myocytes were isolated as described previously (see Supplementary material online, available at http://www.sciencedirect.com).21 This investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996) and was approved by the Institutional Laboratory Animal Care and Use Committee.

2.2. Measurement of peroxynitrite release rate
Electron paramagnetic resonance (EPR) spectroscopy with 1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine hydrochloride (CP-H; Alexis, Lausen, Switzerland) was used to measure the rate of peroxynitrite release from SIN-1 under our experimental conditions as previously described (see Supplementary material online).22

2.3. Simultaneous measurement of cellular Ca2+ transients and myocyte shortening
Ca2+ transients and myocyte shortening were measured in isolated myocytes exposed to various experimental solutions (control, ISO, ISO+SIN-1, etc.) as previously described (see Supplementary material online).21 All measurements were recorded at room temperature (22°C).

2.4. Western blot for phosphorylated PLB
Whole hearts were perfused with the various experimental solutions (control, ISO, ISO+SIN-1, etc.) using a Langendorff apparatus, homogenized, and analysed via western blot as previously described (see Supplementary material online).21 Membranes were probed using either a custom antibody to pentameric PLB (Zymed, San Francisco, CA, USA) or phosphorylated PLBSer16 (Cyclacel, Dundee, UK) or phosphorylated PLBThr17 (Cyclacel).

2.5. Solutions and drugs
Normal Tyrode control solution consisted of (in mmol/L): NaCl (140), KCl (4), MgCl2 (1), CaCl2 (1), Glucose (10), and HEPES (5); pH = 7.4 adjusted with NaOH and/or HCl. Isoproterenol was used as a non-specific ß-adrenergic agonist (ISO; Sigma, St. Louis, MO, USA). 3-Morpholinosydnonimine (SIN-1; Alexis) was used as a peroxynitrite donor. Okadaic acid (Sigma) was used as a PP1/PP2a inhibitor. 5,10,15,20-Tetrakis-[4-sulfonatophenyl]-porphyrinato-iron[III] (FeTPPS; Calbiochem, La Jolla, CA, USA) was used as a specific peroxynitrite decomposition catalyst. Forskolin (Sigma) was used as an adenylate cyclase activator. All solutions were made fresh daily.

2.6. Statistics
Data are presented as mean ± SEM. Statistical significance (P < 0.05) was determined between groups using an ANOVA (followed by Neuman–Keuls test) for multiple groups or a Student's paired t-test for two groups.


   3. Results
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
4. Discussion
 Supplementary material
 Funding
 References
 
3.1. Peroxynitrite production by SIN-1
Using EPR spectroscopy with CP-H, we determined the rate of peroxynitrite release by 200 µmol/L SIN-1 under our experimental conditions (normal Tyrode control solution, 22°C). At this concentration, SIN-1 released 18 nmol L–1min–1 of peroxynitrite over the same time course as our functional/biochemical experiments.

3.2. Negative inotropic effect of SIN-1 on WT myocyte function
We examined the effect of SIN-1 (200 µmol/L) on the maximal ß-adrenergic response in isolated WT myocytes. Ca2+ transients and myocyte shortening were simultaneously recorded in response to various experimental conditions, as shown in Figure 1A. Upon reaching steady state in our normal Tyrode control solution (Ca2+ transient, 0.8 ± 0.2 {Delta}F/F0; shortening, 3.8 ± 0.8 µm), perfusion with a maximal dose of ISO (1 µmol/L) produced a large increase in Ca2+ transient amplitude and shortening (Ca2+ transient, 1.4 ± 0.2 {Delta}F/F0; shortening, 20.2 ± 3.6 µm) in WT myocytes (n = 10/5 hearts). After reaching steady state, co-infusion of 1 µmol/L ISO with 200 µmol/L SIN-1 significantly reduced ß-adrenergic-stimulated Ca2+ transients and myocyte shortening in WT myocytes (Ca2+ transient, 1.1 ± 0.2 {Delta}F/F0; shortening, 14.8 ± 3.4 µm, P < 0.05 vs. ISO). Ca2+ transient and myocyte shortening amplitudes were used to determine the % {Delta} from control (Figure 1B) and the % {Delta} from ISO. SIN-1 reduced ß-adrenergic stimulation in WT myocytes regardless of whether myocytes were co-infused with ISO+SIN-1 prior to or after superfusion with ISO alone.


Figure 1
View larger version (17K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 1 SIN-1 decreases ß-adrenergic stimulation in WT myocytes. (A) Individual, steady-state shortening (top) and Ca2+ transient (bottom) traces representing the anti-adrenergic effect of SIN-1 in a WT myocyte. (B) Pooled data (mean ± SEM) expressed as a % {Delta} from control demonstrating the effect of ISO (1 µmol/L, clear bar) and ISO+SIN-1 (200 µmol/L, filled bar) on shortening (top) and Ca2+ transients (bottom) in WT myocytes; *P < 0.05 vs. ISO. (C) FeTPPS inhibits the anti-adrenergic effect of SIN-1 in WT myocytes. Pooled data (mean ± SEM) expressed as % {Delta} from ISO demonstrating the effect of SIN-1 on ß-adrenergic-stimulated shortening (top) and Ca2+ transients (bottom) in WT (clear bar, B) and WT+FeTPPS (filled bar) myocytes. *P < 0.01 vs. WT. (D) The anti-adrenergic effect of SIN-1 is not due to ISO oxidation. Pooled data (mean ± SEM) expressed as % {Delta} from ISO demonstrating the effect of SIN-1 on ß-adrenergic-stimulated shortening (top) and Ca2+ transients (bottom) in WT (clear bar, C) vs. ISO washout (WO) in WT myocytes (filled bar). *P < 0.01 vs. WT.

 
Perfusion of WT myocytes (n = 18/4 hearts) with SIN-1 during sub-maximal ISO stimulation (0.01 µmol/L) also produced a significant reduction in Ca2+ transient amplitude and myocyte shortening (Ca2+ transient, –12 ± 2%; shortening, –13 ± 5% {Delta} from ISO, P < 0.05 vs. ISO). However, the anti-adrenergic effect of SIN-1 was not as great during sub-maximal ISO stimulation compared with maximal ISO (Ca2+ transient, –17 ± 4%; shortening, –28 ± 5% {Delta} from ISO). Additionally, perfusion with 200 µmol/L SIN-1 alone (n = 10/5 hearts) had no effect on contractility (Ca2+ transient, 0.7 ± 0.2 {Delta}F/F0; shortening, 5.2 ± 1.0 µm) compared with WT myocyte function in normal Tyrode control solution alone (Ca2+ transient, 0.7 ± 0.3 {Delta}F/F0; shortening, 5.0 ± 0.8 µm).

3.3. SIN-1-induced ß-adrenergic hyporesponsiveness results from peroxynitrite
As SIN-1 is not a straightforward donor of peroxynitrite, we sought to confirm the causal species responsible for the anti-adrenergic effects of SIN-1. Upon reaching steady state in our normal Tyrode control solution (Ca2+ transient, 1.4 ± 0.2 {Delta}F/F0; shortening, 3.0 ± 0.3 µm), perfusion with a maximal dose of ISO (1 µmol/L) produced a large increase in Ca2+ transient amplitude and myocyte shortening (Ca2+ transient, 4.9±0.3 {Delta}F/F0; shortening, 14.2 ± 2.2 µm) in WT myocytes (n = 21/3 hearts). Co-infusion of WT myocytes with 1 µmol/L ISO+200 µmol/L SIN-1 and 10 µmol/L FeTPPS, a specific peroxynitrite decomposition catalyst,23 alleviated the anti-adrenergic effects of SIN-1 during maximal ß-adrenergic stimulation (Ca2+ transient, 4.6 ± 0.3 {Delta}F/F0; shortening, 13.8 ± 2.2 µm) compared with WT myocytes not treated with FeTPPS. This effect is shown in Figure 1C, which shows the % {Delta} from ISO, and thus implicates peroxynitrite as the causal species. Additionally, perfusion with 1 µmol/L ISO+10 µmol/L FeTPPS alone did not have a significant effect on the myocyte response to ISO (Ca2+ transient, 3.7 ± 0.8 {Delta}F/F0; shortening, 9.2 ± 2.8 µm) compared with the myocyte response to 1 µmol/L ISO alone (Ca2+ transient, 3.6 ± 0.7 {Delta}F/F0; shortening, 10.2 ± 2.8 µm).

The possibility also exists for peroxynitrite to oxidize catecholamines into inactive aminochromes.15,24,25 Therefore, experiments were performed simulating the oxidation of ISO by SIN-1. Following a steady-state response to 1 µmol/L ISO, WT myocytes (n = 5/3 hearts) were perfused with control solution (normal Tyrode) in order to washout the effects of ISO (see Supplementary material online, Figure S1). However, washout only resulted in a slight decrease in Ca2+ transient amplitude and myocyte shortening over a 5 min period (Ca2+ transient, –3 ± 1%; shortening, –3 ± 3%{Delta} from ISO), while the maximal effect of SIN-1 generally occurred within 3 min and was much greater than that produced by ISO washout alone (Figure 1D; Ca2+ transient, –17 ± 4%; shortening, –28 ± 5% {Delta} from ISO, P < 0.01 vs. ISO washout). Additionally, experiments using forskolin (10 µmol/L), a direct activator of adenylate cyclase, were used to verify that peroxynitrite was not primarily affecting targets upstream of adenylate cyclase, including ISO oxidation. Perfusion with 1 µmol/L forskolin induced an increase in myocyte Ca2+ transients and shortening, similar to the effect seen with 1 µmol/L ISO, but upon co-infusion with 1 µmol/L forskolin+200 µmol/L SIN-1, a significant anti-adrenergic effect remained (data not shown).

3.4. Effect of SIN-1 on ß-adrenergic-stimulated PLB–/– myocyte function
In our previous study, PLB was identified as a potential target of SIN-1 signalling.16 Therefore, we examined the effect of SIN-1 on the ß-adrenergic response in isolated PLB–/– myocytes. PLB–/– myocytes (n = 15/7 hearts) showed the typical enhanced basal contractility (Ca2+ transient, 1.9 ± 0.3 {Delta}F/F0; shortening, 10.2 ± 1.2 µm), as shown in Figure 2A. Thus, PLB–/– myocytes exhibited a reduced ß-adrenergic responsiveness to 1 µmol/L ISO (Ca2+ transient, 2.3 ± 0.8 {Delta}F/F0; shortening: 15.2 ± 2.4 µm) compared with WT, as has been demonstrated previously.26 After reaching steady state, co-infusion with 1 µmol/L ISO+200 µmol/L SIN-1 had surprisingly little effect on the PLB–/– myocytes (Ca2+ transient, 2.3 ± 0.8 {Delta}F/F0; shortening, 15.6 ± 3.0 µm). Ca2+ transient and myocyte shortening amplitudes were used to determine the % {Delta} from control (Figure 2B) and the % {Delta} from ISO. SIN-1 did not affect ß-adrenergic responsiveness in PLB–/– myocytes regardless of whether myocytes were co-infused with ISO+SIN-1 prior to or after superfusion with ISO alone. Thus, the anti-adrenergic effect of SIN-1 was significantly greater in WT compared with PLB–/– myocytes (Figure 2C; Ca2+ transient, –17 ± 4 and –3 ± 3%; shortening, –28 ± 5 and –2 ± 4% {Delta} from ISO, P < 0.01), and therefore indicates that PLB is a significant target in this peroxynitrite signalling pathway. Additionally, perfusion with 200 µmol/L SIN-1 alone (n = 7/4 hearts) had no significant effect on contractility (Ca2+ transient, 1.1 ± 0.2 {Delta}F/F0; shortening, 11.6 ± 4.0 µm) compared with PLB–/– myocyte function in normal Tyrode control solution alone (Ca2+ transient, 1.2 ± 0.2 {Delta}F/F0; shortening, 12.2 ± 4.0 µm).


Figure 2
View larger version (20K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 2 SIN-1 has no effect in PLB–/– myocytes. (A) Individual, steady-state shortening (top) and Ca2+ transient (bottom) traces representing the lack of an anti-adrenergic effect of SIN-1 in a PLB–/– myocyte. (B) Pooled data (mean ± SEM) expressed as % {Delta} from control demonstrating the effect of ISO (1 µmol/L, clear bar) and ISO+SIN-1 (200 µmol/L, filled bar) on shortening (top) and Ca2+ transients (bottom) in PLB–/– myocytes. P > 0.05. (C) The anti-adrenergic effect of SIN-1 is greater in WT compared with PLB–/– myocytes. Pooled data (mean ± SEM) expressed as % {Delta} from ISO demonstrating the effect of SIN-1 on ß-adrenergic-stimulated shortening (top) and Ca2+ transients (bottom) in WT (clear bar, data derived from Figure 1C) and PLB–/– (filled bar) myocytes. *P < 0.01 vs. WT.

 
3.5. Effect of SIN-1 on PLB phosphorylation
After identifying PLB as a target for peroxynitrite signalling, we further investigated its role by examining the effect of SIN-1 on PKA-dependent PLBSer16 phosphorylation in WT hearts (n = 5 hearts/group). As expected, 0.1 µmol/L ISO caused a large increase in PLBSer16 phosphorylation [Figure 3; 266 ± 29 AU (arbitrary units)] compared with control (66 ± 13 AU). However, upon perfusion with 0.1 µmol/L ISO + 200 µmol/L SIN-1, a significant decrease in PLBSer16 phosphorylation was observed (163 ± 18 AU). This reduction in PLBSer16 phosphorylation is likely responsible for the anti-adrenergic effects of SIN-1, as dephosphorylated PLB will likely re-associate with SERCA, thus reducing the SR Ca2+ load and myocyte contractility. No differences were observed in PLBtotal between groups or in phosphorylation at the CaMKII-dependent Thr17 site with 0.1 µmol/L ISO or 0.1 µmol/L ISO + 200 µmol/L SIN-1 (data not shown). This result with PLBThr17 phosphorylation should be expected as CaMKII would not have sufficient time in which to be activated and phosphorylate this site during the time course of our experiments.27


Figure 3
View larger version (29K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 3 SIN-1 decreases ß-adrenergic-stimulated PLBSer16 phosphorylation. (A) Representative western blot specific for PLBSer16 phosphorylation (10, 20 µg protein loading) and pentameric PLBtotal (2, 4 µg protein loading). (B) Pooled data (mean ± SEM) for PLBSer16 phosphorylation (P-PLBSer16) with control (NT, clear bar), ISO (0.1 µmol/L, black bar), or ISO+SIN-1 (200 µmol/L, grey bar). Data displayed as arbitrary units (AU). *P < 0.0001 vs. Cont, **P < 0.01 vs. ISO.

 
3.6. Effect of PP1 and PP2a inhibition on myocyte function
We studied the SIN-1-induced decrease in PLBSer16 phosphorylation further by examining the functional effects of protein phosphatase inhibition in WT myocytes. We repeated the same functional experiments described earlier. However, this time WT myocytes were pre-incubated with okadaic acid, an inhibitor of PP1 and PP2a activity. Upon inhibition with 5 µmol/L okadaic acid (n = 13/3 hearts), we observed a significant increase in basal contractility (Ca2+ transient, 1.6 ± 0.2 {Delta}F/F0; shortening, 7.8 ± 1.4 µm) compared with WT myocytes not pre-incubated with okadaic acid (Ca2+ transient, 0.8 ± 0.2 {Delta}F/F0; shortening, 3.8 ± 0.8 µm, P < 0.05 vs. WT + okadaic acid). The increased basal contractility resulted in a reduction in the ß-adrenergic reserve compared with normal WT myocytes (Ca2+ transient, 1.8 ± 0.2 {Delta}F/F0; shortening: 14.2 ± 2.2 µm). Pre-incubation with 5 µmol/L okadaic acid, however, did alleviate the anti-adrenergic effects of SIN-1 (Ca2+ transient, 1.7 ± 0.3 {Delta}F/F0; shortening, 14.0 ± 2.6 µm). We reduced the concentration of okadaic acid to 1 µmol/L (n = 18/3 hearts) in order to decrease its effect on basal function (Ca2+ transient, 0.6 ± 0.1 {Delta}F/F0; shortening: 4.2 ± 1.0 µm; Figure 4A), and preserve the response to ISO (Ca2+ transient: 1.4 ± 0.2 {Delta}F/F0; shortening, 15.4 ± 2.8 µm) compared with WT myocytes not pre-incubated with okadaic acid. Upon perfusion with 1 µmol/L ISO+200 µmol/L SIN-1, we observed only minimal changes in Ca2+ transient amplitude, and cell shortening in myocytes pre-incubated with 1 µmol/L okadaic acid (Ca2+ transient, 1.3 ± 0.2 {Delta}F/F0; shortening, 15.2 ± 3.0 µm, P < 0.01 vs. WT okadaic acid). The preventative effect of okadaic acid pre-incubation is shown in Figure 4B, which shows the % {Delta} from ISO. These data indicate that SIN-1 exerts anti-adrenergic effects via activation of protein phosphatases.


Figure 4
View larger version (22K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 4 Okadaic acid prevents the effects of SIN-1 in WT myocytes. (A) Individual, steady-state shortening (top) and Ca2+ transient (bottom) traces representing the lack of an anti-adrenergic effect of SIN-1 in a WT myocyte pre-incubated with okadaic acid (1 µmol/L). (B) Pooled data (mean ± SEM) expressed as % {Delta} from ISO demonstrating the effect of SIN-1 on ß-adrenergic-stimulated shortening (top) and Ca2+ transients (bottom) in WT (clear bar, data from Figure 1C) and WT + okadaic acid (filled bar) myocytes. *P < 0.01 vs. WT.

 
3.7. Effect of PP1 and PP2a inhibition on PLB serine 16 phosphorylation
Upon observing that protein phosphatase inhibition alleviated the functional effects of SIN-1 in WT myocytes, we sought to examine the effect of PP1 and PP2a inhibition on PLBSer16 phosphorylation. We repeated the same biochemical experiments described earlier. This time, however, hearts were perfused with 1 µmol/L okadaic acid in order to inhibit protein phosphatase activity, prior to perfusion with 0.1 µmol/L ISO or 0.1 µmol/L ISO + 200 µmol/L SIN-1 (n = 4 hearts/group). As expected, pre-treatment with okadaic acid alone led to a slight increase in basal PLBSer16 phosphorylation. Upon perfusion with 0.1 µmol/L ISO + 200 µmol/L SIN-1, however, the decrease in PLBSer16 phosphorylation was alleviated compared with ISO alone (139 ± 4 vs. 134 ± 7 AU), as seen in % {Delta} from ISO shown in Figure 5B. No differences were observed in PLBtotal. These data further implicate protein phosphatases in the anti-adrenergic effects of the peroxynitrite donor, SIN-1.


Figure 5
View larger version (19K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 5 Okadaic acid (OA) prevents the SIN-1-induced decrease in PLBSer16 phosphorylation. (A) Representative western blot (20 µg protein loading) specific for PLBSer16 phosphorylation and pentameric PLBtotal (4 µg protein loading). (B) Pooled data (mean ± SEM) expressed as % {Delta} from ISO demonstrating the effect of SIN-1 on ß-adrenergic-stimulated PLBSer16 phosphorylation (P-PLBSer16) with (filled bar) and without (clear bar, data derived from Figure 4) protein phosphatase inhibition. *P < 0.01 vs. WT.

 

   4. Discussion
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
 4. Discussion
Supplementary material
 Funding
 References
 
Few studies have examined the mechanism(s) underlying the effects of peroxynitrite on ß-adrenergic responsiveness in the mammalian myocardium. There are many studies demonstrating both positive and negative effects of peroxynitrite on myocardial contractility,13–20 but the majority of these studies addressed effects on basal contractility and not on ß-adrenergic responsiveness. Our study, however, demonstrates that peroxynitrite (18 nmol L–1 min–1), produced via SIN-1, serves to reduce ß-adrenergic responsiveness in murine cardiomyocytes. Upon perfusion with SIN-1, a subsequent decrease in ß-adrenergic-stimulated Ca2+ transient amplitude and myocyte shortening was observed in WT myocytes. The peroxynitrite decomposition catalyst, FeTPPS, reversed the anti-adrenergic effects of SIN-1. We examined the excitation–contraction coupling protein PLB as a potential target in the peroxynitrite pathway and observed that SIN-1 was without effect in PLB–/– knockout myocytes. A further examination of PLB detected decreased ß-adrenergic-stimulated PLBSer16 phosphorylation upon perfusion with SIN-1. Therefore, it is likely that PLB is an end target of peroxynitrite signalling and serves to alter Ca2+ handling in the cardiomyocyte. Additional experiments using okadaic acid, a protein phosphatase inhibitor, suggest that peroxynitrite activates protein phosphatases that ultimately lead to the anti-adrenergic effects of SIN-1. These findings serve to clarify the effects of peroxynitrite production on cardiac contractility and provide a potential mechanism for the observed ß-adrenergic hyporesponsiveness.

4.1. SIN-1 reduces ß-adrenergic stimulation in WT myocytes
Previous studies have demonstrated the anti-adrenergic effects of the peroxynitrite donor, SIN-1, in isolated cardiomyocytes.16,17 We confirmed these results in murine cardiomyocytes, in that SIN-1 induced a decrease in Ca2+ transient amplitude and myocyte shortening during the maximal ß-adrenergic stimulation (Figure 1). Additionally, SIN-1 had no effect on basal contractility, which indicates that 200 µmol/L SIN-1 exclusively modulates the ß-adrenergic responsiveness.

SIN-1 is considered to be a peroxynitrite donor, as it breaks down to form nitric oxide (NO) and superoxide (O2–).28–30 Nitric oxide and superoxide will subsequently couple to form peroxynitrite (ONOO–). However, SIN-1 has a complex chemistry and other reactive species may be formed.31 In our studies, peroxynitrite was confirmed as the causal species, as the peroxynitrite decomposition catalyst, FeTPPS, alleviated the anti-adrenergic effects of SIN-1 (Figure 1).

Many reports in the literature also suggest that it is possible for catecholamines to be oxidized into aminochromes by peroxynitrite.15,24,25 ISO washout experiments, however, demonstrated that this was not the case. The washout of ISO, which simulated ISO oxidation, resulted in only a slight decrease in myocyte contractility, whereas SIN-1 produced a strong anti-adrenergic effect (Figure 1). Additionally, experiments with forskolin, an activator of adenylate cyclase, showed that the primary effect of SIN-1 was not mediated via targets upstream of adenylate cyclase, as SIN-1 still produced anti-adrenergic effects. Thus, in our experimental setting, it is highly unlikely that the main effect of SIN-1 is exerted via oxidation of ISO, but by a direct effect on myocyte Ca2+ handling. Further, it is unlikely that the ß-adrenergic receptor itself or any ß-adrenergic-activated G-coupled proteins are targeted by SIN-1, as the anti-adrenergic effects of SIN-1 were still present upon the direct activation of adenylate cyclase with forskolin. We therefore decided to investigate the role of PLB in this peroxynitrite-induced ß-adrenergic hyporesponsiveness.

4.2. SIN-1 and PLB–/– myocyte function
Although we observed the anti-adrenergic effects of SIN-1 in WT myocytes, we saw no effect of SIN-1 on PLB–/– myocytes (Figure 2). This would indicate that SIN-1, and thus peroxynitrite, exerts anti-adrenergic effects by targeting the excitation–contraction coupling protein PLB.

4.3. SIN-1 reduces PLB serine 16 phosphorylation
We investigated the role of PLB further by examining its PKA-dependent Ser16 phosphorylation site as a potential mechanism for the functional effects of SIN-1. Studies have shown that there is a reduction in PLBSer16 phosphorylation in heart failure,32–34 potentially resulting in reduced Ca2+ sensitivity of the SERCA pump and abnormal Ca2+ handling.35 Examination of this phosphorylation site revealed an increase in PLBSer16 phosphorylation with ISO (Figure 3). This is to be expected as ISO activates the ß-adrenergic pathway, resulting in PKA activation. However, SIN-1 induced a significant reduction in ß-adrenergic-stimulated PLBSer16 phosphorylation. These data provide a potential mechanism for the functional effects of SIN-1, as decreased PLBSer16 phosphorylation would increase the interaction of PLB with SERCA, thus reducing SR Ca2+ load and myocyte contractility. This reduction in PLBSer16 phosphorylation may be a key component of the contractile dysfunction observed in heart failure, and would serve to reduce the affinity of the SERCA pump for Ca2+.

4.4. Protein phosphatase inhibition alleviates anti-adrenergic effects of SIN-1
Our current data show that peroxynitrite exposure leads to a reduction in PLBSer16 phosphorylation. Additionally, one study has demonstrated an interaction between peroxynitrite and protein phosphatase activity in erythrocytes,36 but no studies have investigated a direct link in cardiomyocytes. We therefore decided to investigate alterations in protein phosphatases as a potential mechanism for the functional effects of SIN-1, as Neumann et al.37 demonstrated an increased PP1 activity in preparations from failing human hearts vs. non-failing hearts using phosphorylated PLB as the substrate. Inhibition of protein phosphatase activity with okadaic acid (1 µmol/L) resulted in no significant changes in basal contractility or in response to ISO compared with normal WT myocytes. Protein phosphatase inhibition, however, alleviated the anti-adrenergic effect of SIN-1 in myocytes pre-incubated with okadaic acid (Figure 4), providing a potential mechanism for the reduction in PLBSer16 phosphorylation.

4.5. Protein phosphatase inhibition prevents the SIN-1-induced decrease in PLB serine 16 phosphorylation
The inhibition of protein phosphatase activity not only prevented the functional effect of SIN-1 in WT myocytes, but also alleviated the SIN-1-induced decrease in PLBSer16 phosphorylation. Pre-incubation with okadaic acid (1 µmol/L) resulted in a slight increase in PLBSer16 phosphorylation. However, upon perfusion with SIN-1, no decrease in ISO-stimulated phosphorylation was observed in hearts perfused with okadaic acid (Figure 5).

4.6. Physiological relevance of SIN-1 concentration
The concentration of SIN-1 (200 µmol/L) used in this study was determined to release peroxynitrite at a rate of 18 nmol L–1 min–1 under experimental conditions. In terms of physiological relevance, myocardial peroxynitrite injury is often associated with inducible nitric oxide synthase (iNOS, NOS2) expression.38 We have previously shown that acute inhibition of NOS2 in failing human myocytes increased the Ca2+ transient and myocyte shortening amplitude during ß-adrenergic stimulation.39 This same functional phenomenon was observed in our current study (i.e. peroxynitrite decreased the ß-adrenergic response). Also, NOS2 inhibition had no effect on basal function in failing human myocytes. Once again the same phenomenon was observed in our current study. Thus, we believe that the concentration of SIN-1 is relevant under pathophysiological conditions (i.e. heart failure) and may explain the mechanism responsible for the reversible, NOS2-induced ß-adrenergic hyporesponsiveness. Additionally, moderately high concentrations of peroxynitrite (>25 µmol/L) have been shown to have effects on basal contractility,15 whereas extremely high concentrations of peroxynitrite (>200 µmol/L) have been shown to induce a state of rigour,40 and neither of these effects were observed in our study.

In conclusion, the peroxynitrite donor, SIN-1, reduces ß-adrenergic stimulation by ultimately targeting PLB. SIN-1 exerts anti-adrenergic effects by reducing PKA-dependent PLBSer16 phosphorylation via activation of protein phosphatases. A functional effect on ß-adrenergic stimulation is yielded through a disruption in Ca2+ handling. As SIN-1 has also been shown to reduce cAMP levels in cardiomyocytes,16 future studies will address the effects of SIN-1 on adenylate cyclase activity, cAMP levels, and PKA activity. Previous studies have also shown that peroxynitrite can directly inactivate SERCA.41,42 Additionally, peroxynitrite has been demonstrated to affect other excitation–contraction coupling proteins, including troponin I, RyR, and the Na+/Ca2+ exchanger.40,43,44 The effects of peroxynitrite, however, may not have been observed in PLB–/– myocytes due to their hyperdynamic contractile state, and because of concentration and time-dependent effects. Therefore, a direct effect of peroxynitrite on any of the aforementioned excitation–contraction coupling proteins cannot be completely ruled out.

In many cardiomyopathies, including heart failure, nitric oxide production is increased because of the expression of NOS2.39,45 Additionally, superoxide production is increased via NADPH and/or xanthine oxidoreductase.46,47 Elevated nitric oxide and superoxide production could lead to the formation of high levels of peroxynitrite. Furthermore, the expression of NOS2 by itself may lead to peroxynitrite formation and myocardial injury.38,39,48 Thus, our current observation provides a plausible mechanism for the diminished ß-adrenergic responsiveness observed in heart failure, as peroxynitrite formation and protein phosphatase activity have been shown to be increased,10–12,37,49 while PLBSer16 phosphorylation was shown to be decreased.32–34 Therefore, this peroxynitrite signalling cascade could be a key pathway in the decreased PLB phosphorylation and resulting dysfunction observed in heart failure and other cardiomyopathies.


   Supplementary material
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
 4. Discussion
 Supplementary material
Funding
 References
 
Supplementary material is available at Cardiovascular Research online.


   Funding
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
 4. Discussion
 Supplementary material
 Funding
References
 
American Heart Association (0715159B, M.J.K.; 0725560B, H.W.; 0335385Z, M.T.Z.) and the National Institutes of Health (R01HL079283, M.T.Z.; R01HL063744, J.L.Z.; P01HL065608, J.L.Z.).


   Acknowledgements
 
We would like to thank Dr Evangelia G. Kranias (University of Cincinnati) for providing the PLB–/– mice.

Conflict of interest: none declared.


   References
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
 4. Discussion
 Supplementary material
 Funding
 References
 

  1. Bers DM. Cardiac excitation-contraction coupling. Nature (2002) 415:198–205.[CrossRef][Medline]
  2. Bassani JW, Yuan W, Bers DM. Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. Am J Physiol (1995) 268:C1313–C1319.[Web of Science][Medline]
  3. Bers DM, Ziolo MT. When is cAMP not cAMP? Effects of compartmentalization. Circ Res (2001) 89:373–375.[Free Full Text]
  4. Chu G, Lester JW, Young KB, Luo W, Zhai J, Kranias EG. A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists. J Biol Chem (2000) 275:38938–38943.[Abstract/Free Full Text]
  5. MacDougall LK, Jones LR, Cohen P. Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur J Biochem (1991) 196:725–734.[Web of Science][Medline]
  6. Cheung PY, Wang W, Schulz R. Glutathione protects against myocardial ischemia-reperfusion injury by detoxifying peroxynitrite. J Mol Cell Cardiol (2000) 32:1669–1678.[CrossRef][Web of Science][Medline]
  7. Zhao X, Chen YR, He G, Zhang A, Druhan LJ, Strauch AR, et al. Endothelial nitric oxide synthase (NOS3) knockout decreases NOS2 induction, limiting hyperoxygenation and conferring protection in the postischemic heart. Am J Physiol Heart Circ Physiol (2007) 292:H1541–H1550.[Abstract/Free Full Text]
  8. Khadour FH, Panas D, Ferdinandy P, Schulze C, Csont T, Lalu MM, et al. Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. Am J Physiol Heart Circ Physiol (2002) 283:H1108–H1115.[Abstract/Free Full Text]
  9. Lancel S, Tissier S, Mordon S, Marechal X, Depontieu F, Scherpereel A, et al. Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. J Am Coll Cardiol (2004) 43:2348–2358.[Abstract/Free Full Text]
  10. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res (2000) 87:241–247.[Abstract/Free Full Text]
  11. Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res (2001) 49:798–807.[Abstract/Free Full Text]
  12. Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res (2007) 100:1089–1098.[Abstract/Free Full Text]
  13. Lopez BL, Liu GL, Christopher TA, Ma XL. Peroxynitrite, the product of nitric oxide and superoxide, causes myocardial injury in the isolated perfused rat heart. Coron Artery Dis (1997) 8:149–153.[Web of Science][Medline]
  14. Ferdinandy P, Panas D, Schulz R. Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. Am J Physiol (1999) 276:H1861–H1867.[Web of Science][Medline]
  15. Katori T, Donzelli S, Tocchetti CG, Miranda KM, Cormaci G, Thomas DD, et al. Peroxynitrite and myocardial contractility: in vivo versus in vitro effects. Free Radic Biol Med (2006) 41:1606–1618.[CrossRef][Web of Science][Medline]
  16. Stojanovic MO, Ziolo MT, Wahler GM, Wolska BM. Anti-adrenergic effects of nitric oxide donor SIN-1 in rat cardiac myocytes. Am J Physiol Cell Physiol (2001) 281:C342–C349.[Abstract/Free Full Text]
  17. Yin X, Shan Q, Deng C, Bourreau JP. Effect of SIN-1 in rat ventricular myocytes: interference with beta-adrenergic stimulation. Life Sci (2002) 71:287–297.[CrossRef][Web of Science][Medline]
  18. Chesnais JM, Fischmeister R, Mery PF. Peroxynitrite is a positive inotropic agent in atrial and ventricular fibres of the frog heart. J Physiol (1999) 521:375–388.[Abstract/Free Full Text]
  19. Chesnais JM, Fischmeister R, Mery PF. Positive and negative inotropic effects of NO donors in atrial and ventricular fibres of the frog heart. J Physiol (1999) 518:449–461.[Abstract/Free Full Text]
  20. Paolocci N, Ekelund UE, Isoda T, Ozaki M, Vandegaer K, Georgakopoulos D, et al. cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. Am J Physiol Heart Circ Physiol (2000) 279:H1982–H1988.[Abstract/Free Full Text]
  21. Babu GJ, Bhupathy P, Petrashevskaya NN, Wang H, Raman S, Wheeler D, et al. Targeted overexpression of sarcolipin in the mouse heart decreases sarcoplasmic reticulum calcium transport and cardiac contractility. J Biol Chem (2006) 281:3972–3979.[Abstract/Free Full Text]
  22. Dikalov S, Skatchkov M, Bassenge E. Spin trapping of superoxide radicals and peroxynitrite by 1-hydroxy-3-carboxy-pyrrolidine and 1-hydroxy-2,2,6, 6-tetramethyl-4-oxo-piperidine and the stability of corresponding nitroxyl radicals towards biological reductants. Biochem Biophys Res Commun (1997) 231:701–704.[CrossRef][Web of Science][Medline]
  23. Misko TP, Highkin MK, Veenhuizen AW, Manning PT, Stern MK, Currie MG, et al. Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem (1998) 273:15646–15653.[Abstract/Free Full Text]
  24. Shelkovnikov S, Gonick HC. Peroxynitrite but not nitric oxide donors destroys epinephrine: HPLC measurement and rat aorta contractility. Life Sci (2004) 75:2765–2773.[CrossRef][Web of Science][Medline]
  25. Takakura K, Xiaohong W, Takeuchi K, Yasuda Y, Fukuda S. Deactivation of norepinephrine by peroxynitrite as a new pathogenesis in the hypotension of septic shock. Anesthesiology (2003) 98:928–934.[CrossRef][Web of Science][Medline]
  26. Wolska BM, Stojanovic MO, Luo W, Kranias EG, Solaro RJ. Effect of ablation of phospholamban on dynamics of cardiac myocyte contraction and intracellular Ca2+. Am J Physiol (1996) 271:C391–C397.[Web of Science][Medline]
  27. Wang W, Zhu W, Wang S, Yang D, Crow MT, Xiao RP, et al. Sustained beta1-adrenergic stimulation modulates cardiac contractility by Ca2+/calmodulin kinase signaling pathway. Circ Res (2004) 95:798–806.[Abstract/Free Full Text]
  28. Feelisch M, Ostrowski J, Noack E. On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol (1989) 14:S13–S22.
  29. Singh RJ, Hogg N, Joseph J, Konorev E, Kalyanaraman B. The peroxynitrite generator, SIN-1, becomes a nitric oxide donor in the presence of electron acceptors. Arch Biochem Biophys (1999) 361:331–339.[CrossRef][Web of Science][Medline]
  30. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol (1996) 271:C1424–C1437.[Web of Science][Medline]
  31. Kirsch M, Lomonosova EE, Korth HG, Sustmann R, de Groot H. Hydrogen peroxide formation by reaction of peroxynitrite with HEPES and related tertiary amines. Implications for a general mechanism. J Biol Chem (1998) 273:12716–12724.[Abstract/Free Full Text]
  32. Bartel S, Stein B, Eschenhagen T, Mende U, Neumann J, Schmitz W, et al. Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts. Mol Cell Biochem (1996) 157:171–179.[CrossRef][Web of Science][Medline]
  33. Schwinger RH, Munch G, Bolck B, Karczewski P, Krause EG, Erdmann E. Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol (1999) 31:479–491.[CrossRef][Web of Science][Medline]
  34. Sande JB, Sjaastad I, Hoen IB, Bokenes J, Tonnessen T, Holt E, et al. Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc Res (2002) 53:382–391.[Abstract/Free Full Text]
  35. Houser SR, Piacentino V III, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol (2000) 32:1595–1607.[CrossRef][Web of Science][Medline]
  36. Kucherenko Y, Browning J, Tattersall A, Ellory JC, Gibson JS. Effect of peroxynitrite on passive K+ transport in human red blood cells. Cell Physiol Biochem (2005) 15:271–280.[CrossRef][Web of Science][Medline]
  37. Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, et al. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol (1997) 29:265–272.[CrossRef][Web of Science][Medline]
  38. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T, et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest (2002) 109:735–743.[CrossRef][Web of Science][Medline]
  39. Ziolo MT, Maier LS, Piacentino V III, Bossuyt J, Houser SR, Bers DM. Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing human hearts by decreasing Ca2+ transients. Circulation (2004) 109:1886–1891.[Abstract/Free Full Text]
  40. Ishida H, Genka C, Hirota Y, Hamasaki Y, Nakazawa H. Distinct roles of peroxynitrite and hydroxyl radical in triggering stunned myocardium-like impairment of cardiac myocytes in vitro. Mol Cell Biochem (1999) 198:31–38.[CrossRef][Web of Science][Medline]
  41. Knyushko TV, Sharov VS, Williams TD, Schoneich C, Bigelow DJ. 3-Nitrotyrosine modification of SERCA2a in the aging heart: a distinct signature of the cellular redox environment. Biochemistry (2005) 44:13071–13081.[CrossRef][Medline]
  42. Lokuta AJ, Maertz NA, Meethal SV, Potter KT, Kamp TJ, Valdivia HH, et al. Increased nitration of sarcoplasmic reticulum Ca2+/-ATPase in human heart failure. Circulation (2005) 111:988–995.[Abstract/Free Full Text]
  43. Ziolo MT, Katoh H, Bers DM. Expression of inducible nitric oxide synthase depresses beta-adrenergic-stimulated calcium release from the sarcoplasmic reticulum in intact ventricular myocytes. Circulation (2001) 104:2961–2966.[Abstract/Free Full Text]
  44. Rork TH, Hadzimichalis NM, Kappil MA, Merrill GF. Acetaminophen attenuates peroxynitrite-activated matrix metalloproteinase-2-mediated troponin I cleavage in the isolated guinea pig myocardium. J Mol Cell Cardiol (2006) 40:553–561.[CrossRef][Web of Science][Medline]
  45. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol (1998) 32:955–963.[Abstract/Free Full Text]
  46. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol (2003) 41:2164–2171.[Abstract/Free Full Text]
  47. Minhas KM, Saraiva RM, Schuleri KH, Lehrke S, Zheng M, Saliaris AP, et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res (2006) 98:271–279.[Abstract/Free Full Text]
  48. Xia Y, Roman LJ, Masters BS, Zweier JL. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem (1998) 273:22635–22639.[Abstract/Free Full Text]
  49. Gupta RC, Mishra S, Rastogi S, Imai M, Habib O, Sabbah HN. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am J Physiol Heart Circ Physiol (2003) 285:H2373–H2381.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
J. R. Burgoyne and P. Eaton
Transnitrosylating Nitric Oxide Species Directly Activate Type I Protein Kinase A, Providing a Novel Adenylate Cyclase-independent Cross-talk to {beta}-Adrenergic-like Signaling
J. Biol. Chem., October 23, 2009; 284(43): 29260 - 29268.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
H. Wang, M. J. Kohr, D. G. Wheeler, and M. T. Ziolo
Endothelial nitric oxide synthase decreases {beta}-adrenergic responsiveness via inhibition of the L-type Ca2+ current
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1473 - H1480.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
D. Garcia-Dorado, H. M. Piper, and D. A. Eisner
Sarcoplasmic reticulum and mitochondria in cardiac pathophysiology
Cardiovasc Res, January 15, 2008; 77(2): 231 - 233.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
77/2/353    most recent
cvm018v2
cvm018v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kohr, M. J.
Right arrow Articles by Ziolo, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kohr, M. J.
Right arrow Articles by Ziolo, M. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?